Skip to content

Author

Mark A. Magnuson

We have 2 of 21 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

QuantEM: An optimized platform of vision transformer-based models for segmentation and analysis of electron microscopy data

Electron microscopy (EM) is essential for resolving cellular ultrastructure, yet quantitative analysis remains limited by labor-intensive segmentation and the scarcity of generalizable models. Here we present QuantEM, an open-source platform for segmentation and analysis of EM data across imaging modalities, tissues, and species. We assembled the largest curated collection of intracellular EM datasets to date, comprising over 15,000 two-dimensional images and 1,700 three-dimensional acquisitions from more than 600 datasets, including nearly 4,000 newly released acquisitions. Using this resource, we trained an EM-specific vision transformer foundation model and systematically optimized adaptation strategies for organelle segmentation. QuantEM provides pretrained models for mitochondria, endoplasmic reticulum, nuclei, and lipid droplets, integrated with interactive proofreading and downstream quantitative analyses through standalone and napari interfaces. Across diverse naive datasets, QuantEM consistently matches or exceeds existing models on zero-shot segmentation while requiring less data for finetuning. We further demonstrate its utility by revealing previously unrecognized subcellular compartmentation of hepatic glucokinase using immuno-electron microscopy.

Christopher Acree, Evan S. Krystofiak, Katie C. Coate et al. · 0 citations
Open access Jul 2026

Molecular dynamics driving phenotypic divergence among KRAS mutants in pancreatic tumorigenesis.

To define mutation-specific lineage reversion and tumor initiation, Ptf1a-tdTomato mice and multiple KRAS mutants are implemented across several genetic, pharmacologic, and inflammatory perturbations in vivo to deciphering mutation-specific oncogenic trajectories and directing the implementation of KRAS-directed therapeutics.

A. Grimont, David Falvo, W. Sisso et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.